US Army backs Recce’s synthetic antibiotic for burns
Автор: Proactive Investors
Загружено: 2026-02-09
Просмотров: 61
Описание:
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) managing director and CEO James Graham talked with Proactive about the company’s second Cooperative Research and Development Agreement (CRADA) with the United States Army Institute of Surgical Research (USAISR), focused on evaluating its synthetic antibiotic RECCE® 327 Gel (R327G) as a treatment for infected burn wounds.
Graham said the agreement marked a significant milestone for the company and for frontline warfighters, noting it is Recce Pharmaceuticals’ second CRADA with the US Army and the company’s third research program with the US Department of Defense. He explained that the current research will test R327G against staphylococcal bacteria in a burn wound model, describing infected burns as one of the greatest challenges for both military medicine and antibiotic resistance more broadly.
Visit Proactive’s YouTube channel for more interviews and insights, and don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss an update.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
